MÔ TẢ NỒNG ĐỘ HS TROPONIN I VÀ CÁC THÀNH TỐ HỘI CHỨNG CHUYỂN HÓA Ở BỆNH NHÂN NGOẠI TRÚ

Abstract

Background: Metabolic syndrome is a cluster of risk factors including hypertension, dyslipidemia, hyperglycemia and central obesity, affecting approximately 25% of the global adult population, especially in developing countries. In Vietnam, the prevalence of Metabolic syndrome is increasing rapidly, related to poor control of risk factors and industrialized lifestyle; a study in Ho Chi Minh City showed that the prevalence of Metabolic syndrome in adults is 36.2%. Metabolic syndrome is known as a major risk factor for cardiovascular disease – the world's leading cause of death and also the worst consequence of the progression of myocardial damage over many years. Subclinical myocardial damage can be detected early by hs Troponin I - a highly sensitive biomarker - even in people without cardiovascular symptoms. The significant mild elevation of hs Troponin I in non-acute conditions opens up a new direction for assessing cardiovascular risk in Metabolic syndrome patients. However, the relationship between hs Troponin I concentration and each Metabolic syndrome component and the number of components present has not been systematically studied. Therefore, this study was conducted to describe the change in hs Troponin I concentration according to each Metabolic syndrome component, as well as analyze the variation of this concentration according to the number of components present. Objective: Describe the change in hs-Troponin I concentration according to each HCCH component, and analyze the variation in this concentration according to the number of components present. Methods: Cross-sectional study design describes 149 cases of metabolic syndrome and 149 cases without metabolic syndrome who visited Tra Vinh Provincial General Hospital in 2023. Data were collected and analyzed using SPSS software. Results: The analysis results showed that each component of metabolic syndrome had an impact on the slight increase in hs-Troponin I, although the impact level was different for each component as shown through the linear regression model with R< 0.5 and p<0.005. The proportion of patients with hs-Troponin I concentrations >3.8 ng/L increased as the number of metabolic syndrome components increased. Conclusion: Each component of the metabolic syndrome has the potential to increase hs-Troponin I levels. When the components combine into a syndrome, the effects on the heart muscle are more pronounced. Early and coordinated control of the components of the metabolic syndrome is needed to minimize myocardial damage and the risk of future cardiovascular events.